Group 1: Observation of the application of Lonquex(R) (Lipegfilgrastim) for a period of 6 months. Collection of data e.g. about demography, patient status (ECOG), primary disease/tumor anamnesis, ther
Sponsors
Fa. Teva GmbH
Conditions
C50
C56C61
C67
Unknown Phase
Non-Interventional study on treatment with Lipegfilgrastim (Lonquex) in patients with gynecological malignant entities, being treated with myelotoxic chemotherapies.
RecruitingDRKS00008901
Start: 2015-07-22Target: 450Updated: 2025-04-07
Non-Interventional study on treatment with Lipegfilgrastim (Lonquex®) in patients with urological malignant entities, being treated with myelotoxic chemotherapies.
Active, not recruitingDRKS00008907
Start: 2015-07-24Target: 300Updated: 2025-04-07